The European life sciences industry has a long history. Many of the major players trace their roots to before the war, and often began as agricultural or chemical companies. LSIPR takes a look at the leading jurisdictions.
In the past year or so, life sciences companies have outperformed the stock exchange significantly. Though it would be foolish to call this a boom time for the industry, investors know that there is money to be made in developing innovative biotech solutions.
Countries that have not been traditional life sciences powerhouses are wising up, and the next great success story seems as likely to be from India as from Europe. In this context, the traditional powerhouses of the European life sciences industry will need to be smart, while national and regional governments have to think carefully about how to keep them competitive on the global stage.
To continue reading, you need a subscription to WIPR. Start a subscription to WIPR for £455.
In-house feature articles, the archive and expert comment require a paid subscription. Subscribe now.
Want to give it a try? We are offering a two week free trial to the WIPR website – register and select “Free Trial” to begin access to the full WIPR archive and read the latest news, features and expert comment. Begin your free trial here.
Is your 2 week free trial about to end? Upgrade to a 12 month subscription for £455 now.
If you have already subscribed please login.
If you have any technical issues please email James Lynn on firstname.lastname@example.org.
Bayer, biotechnology, pharmaceuticals, Astra,